NCT02922790

Brief Summary

The purpose of the study is to explore how feedback of cellular DNA (Deoxyribonucleic Acid) damage, as a marker of exposure to the genotoxic agents of tobacco smoke, promotes cessation.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
39

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Feb 2017

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 26, 2016

Completed
8 days until next milestone

First Posted

Study publicly available on registry

October 4, 2016

Completed
4 months until next milestone

Study Start

First participant enrolled

February 14, 2017

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 24, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 24, 2017

Completed
Last Updated

January 5, 2018

Status Verified

January 1, 2018

Enrollment Period

5 months

First QC Date

September 26, 2016

Last Update Submit

January 4, 2018

Conditions

Keywords

smokersmokingcigarettecessationDNADNA damageblood drawfeedbackcellulartobaccotobacco smoke

Outcome Measures

Primary Outcomes (8)

  • Degree of participant understanding of materials, to be measured by a survey

    Study will measure the extent to which the biomarker information was understood, as measured by a survey

    week 3

  • Percentage of subjects who show up to the sessions

    Study will collect feasibility data on how many participants come to each visit.

    Week 1

  • Extent to which participants believe the feedback to be accurate

    The study will measure the extent to which DNA damage results would be considered accurate using a survey.

    week 3

  • Degree of participant understanding of materials, to be measured by an interview

    Study will measure the extent to which the biomarker information was understood, as measured by an interview.

    Week 3

  • Percentage of subjects who show up to the sessions

    Study will collect feasibility data on how many participants come to each visit.

    Week 3

  • Extent to which participants believe the feedback to be trustworthy

    The study will measure the extent to which DNA damage results would be considered trustworthy using a survey.

    Week 3

  • Extent to which participants believe the feedback to be accurate

    The study will measure the extent to which DNA damage results would be considered accurate using an interview.

    Week 3

  • Extent to which participants believe the feedback to be trustworthy

    The study will measure the extent to which DNA damage results would be considered trustworthy using an interview.

    Week 3

Secondary Outcomes (7)

  • Effect size of the changes in coherence between the control and biomarker arm from baseline to three months post-intervention on

    Baseline to 3 months

  • Effect size of the change in risk appraisals between the control and biomarker arm from baseline to three months post-intervention on

    Baseline to 3 months

  • Effect size of participant motivation to quit smoking between the control and biomarker arm from baseline to three months post-intervention on

    Baseline to 3 months

  • Effect size of plans to quit smoking between the control and biomarker arm from baseline to three months post-intervention on

    Baseline to 3 months

  • Effect size of mean levels of smoking between the control and biomarker arm at three months post-intervention

    3 months

  • +2 more secondary outcomes

Study Arms (3)

Control

ACTIVE COMPARATOR

Subjects will review standard health information on the health consequences of smoking. Subjects will have blood drawn but it will not be tested for DNA damage.

Behavioral: standard health information

Biomarker feedback

ACTIVE COMPARATOR

Subjects will review this standardized health information, plus receive information on DNA damage along with feedback of their DNA damage. Subjects will have blood drawn and the feedback will be presented at Visit 2.

Behavioral: standard health information plus info. on DNA damage

Biomarker feedback plus

ACTIVE COMPARATOR

Subjects will review this standardized health information, information on DNA damage along with feedback of their DNA damage, and will also will see images of their own cells with and without DNA damage. Subjects will have blood drawn and the feedback and images will be presented at Visit 2.

Behavioral: Subjects will review standard health information and information on DNA damage, plus pictures of their DNA damage

Interventions

Subjects will review standard health information

Control

Subjects will review standard health information and information on DNA damage

Biomarker feedback

Subjects will review standard health information and information on DNA damage, as well as review pictures of their cells' DNA damage

Biomarker feedback plus

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ages 18+
  • smoke \> 5 cig/day during the last week
  • be open to biomarker feedback
  • not actively trying to quit

You may not qualify if:

  • smoker carbon monoxide level(CO \< 10 ppm)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Duke University Medical Center

Durham, North Carolina, 27701, United States

Location

MeSH Terms

Conditions

Smoking

Condition Hierarchy (Ancestors)

Behavior

Study Officials

  • Isaac Lipkus, PhD

    Duke University School of Nursing

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 26, 2016

First Posted

October 4, 2016

Study Start

February 14, 2017

Primary Completion

July 24, 2017

Study Completion

July 24, 2017

Last Updated

January 5, 2018

Record last verified: 2018-01

Data Sharing

IPD Sharing
Will not share

Locations